Latest news with #3SBio
Yahoo
14-07-2025
- Business
- Yahoo
China's Biotech Is Quietly Eating Big Pharma's Lunch
Chinese biotech is no longer playing catch-up it's becoming the main event. In 2024, more than 1,250 innovative drugs entered development in China, nearly overtaking the US and leaving the EU behind. This isn't just a numbers game. Chinese firms like Akeso (AKESF) are now developing therapies that are outperforming global blockbusters like Merck's Keytruda in head-to-head trials. The quality leap has been fast, fueled by regulatory reforms, foreign-trained scientists, and an R&D machine that moves at blistering speed. Data from Norstella shows China now earns more expedited drug reviews than the EU a signal that Western regulators are paying attention. Warning! GuruFocus has detected 7 Warning Signs with AKESF. Multinational pharma isn't waiting around. Pfizer (NYSE:PFE) just cut a $1.2 billion upfront deal with 3SBio. Summit Therapeutics paid $500 million for rights to Akeso's cancer therapy. These aren't niche plays they're big bets on the future. And with China's massive patient pool and streamlined hospital network, companies can run trials in half the time (and at a fraction of the cost) compared to the US. That speed lets Chinese firms launch multiple shots on goal and global players are lining up to license the winners. From cell therapies to obesity drugs, the East is becoming the place where the drug pipeline gets built. But approval is still a long game. US regulators aren't greenlighting drugs based solely on China trial data not yet. And with rising geopolitical tension, some in Washington are sounding alarms over biotech dependencies. Still, the shift is underway. In just five years, the number of top-ranked Chinese drug innovators has quadrupled. Investors watching this space aren't asking whether China will lead the next wave of biotech innovation. They're asking how soon. This article first appeared on GuruFocus.
Nikkei Asia
23-06-2025
- Business
- Nikkei Asia
Chinese biotech is having a 'DeepSeek moment'
Analysts view a current wave of dealmaking as a watershed moment for China's biotech industry and a vital source of capital for domestic firms. CHEN XI and HAN WEI, Caixin In a resounding vote of confidence in China's biotechnology sector, leading global pharmaceutical companies are striking multibillion-dollar deals for innovative therapies developed by Chinese firms. These deals mark a pivotal point for China's role in global drug development and have sparked a capital market frenzy. In late May, Pfizer agreed to pay $1.25 billion upfront to 3SBio, a Shenyang-based biotech firm, for the rights to a promising anti-tumor drug. The agreement could eventually be worth up to $6.05 billion.
Globe and Mail
19-06-2025
- Business
- Globe and Mail
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer's revenues in 2024 and in the first quarter of 2025. Seagen also has some next-generation ADC candidates in its pipeline. Pfizer's oncology revenues grew 7% on an operational basis in the first quarter of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Pfizer has also ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer has also advanced its oncology clinical pipeline with several candidates entering late-stage development, like sasanlimab, vepdegestrant and sigvotatug vedotin. In May, Pfizer inked an exclusive licensing deal with China's 3SBio for the latter's dual PD-1 and VEGF inhibitor, which will strengthen its oncology pipeline. Pfizer is also working on expanding the labels of approved oncology products like Padcev and Adcetris, among others. With all the above developments, Pfizer's future in cancer treatment looks promising. Competition in the Oncology Space Other large players in the oncology space are AstraZeneca AZN, Merck MRK and Bristol-Myers BMY. For AstraZeneca, oncology sales now comprise around 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca's strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). Merck's key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Bristol-Myers' key cancer drug is PD-LI inhibitor, Opdivo, which accounts for around 20% of its total revenues. PFE's Price Performance, Valuation and Estimates Pfizer's stock has declined 6.8% so far this year against an increase of 0.2% for the industry. Image Source: Zacks Investment Research From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 7.77 forward earnings, lower than 15.05 for the industry and the stock's 5-year mean of 10.90. The Zacks Consensus Estimate for 2025 earnings has risen from $2.98 per share to $3.06 per share, while that for 2026 has gone up from $3.00 to $3.09 per share over the past 60 days. Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
Yahoo
17-06-2025
- Business
- Yahoo
Wall Street Can't Ignore This: China's Biotech Stocks Are Exploding--One Is Up 283%
China's biotech sector is on a tear. The Hang Seng Biotech Index has climbed over 60% since Januaryhandily beating China tech's AI-fueled rallythanks to a wave of billion-dollar licensing deals and red-hot IPOs. Pfizer said last month it will pay up to $1.25 billion to license an experimental cancer drug from 3SBio (TRSBF) and invest another $100 million in the firm's stock. Just weeks later, Bristol-Myers Squibb inked a deal worth up to $11.5 billion for a cancer therapy originally licensed by Germany's BioNTech from China's Biotheus. Those two deals alone have ignited a frenzy. 3SBio shares have soared 283% year-to-date. RemeGen, another licensing contender, is up 270% as of June. Investors aren't just chasing dealsthey're also buying into the IPO pipeline. Duality Biotherapeutics, which focuses on cancer immunotherapies, more than doubled on its first day of trading in April and has since gained 189%. Jiangsu Hengrui, China's biggest drugmaker by market value, surged 25% on debut in May. Even more striking? The pace of dealmaking. M&A involving Chinese biotech firms hit $36.9 billion in Q1more than half of global totals. Chinese biotech is having its own DeepSeek moment, said Dong Chen, chief Asia strategist at Pictet Wealth Management, referencing the AI boom that fueled Chinese tech earlier this year. Still, not everyone's chasing the highs. Some healthcare-focused funds are rotating out, preferring stable compounders with steady dividends. Others see the recent mega-deals as one-offs, and aren't ready to assign premium multiples just yet. But even with macro headwinds, analysts like those at Jefferies remain optimistic. Many Chinese biotech firms already operate as partners to U.S. drugmakers, not exportersmeaning tariffs may have limited impact. And with top scientific talent returning home amid geopolitical tensions, R&D momentum could accelerate. In short: China's biotech surge might still be in the early innings. This article first appeared on GuruFocus.
Yahoo
17-06-2025
- Business
- Yahoo
Wall Street Can't Ignore This: China's Biotech Stocks Are Exploding--One Is Up 283%
China's biotech sector is on a tear. The Hang Seng Biotech Index has climbed over 60% since Januaryhandily beating China tech's AI-fueled rallythanks to a wave of billion-dollar licensing deals and red-hot IPOs. Pfizer said last month it will pay up to $1.25 billion to license an experimental cancer drug from 3SBio (TRSBF) and invest another $100 million in the firm's stock. Just weeks later, Bristol-Myers Squibb inked a deal worth up to $11.5 billion for a cancer therapy originally licensed by Germany's BioNTech from China's Biotheus. Those two deals alone have ignited a frenzy. 3SBio shares have soared 283% year-to-date. RemeGen, another licensing contender, is up 270% as of June. Investors aren't just chasing dealsthey're also buying into the IPO pipeline. Duality Biotherapeutics, which focuses on cancer immunotherapies, more than doubled on its first day of trading in April and has since gained 189%. Jiangsu Hengrui, China's biggest drugmaker by market value, surged 25% on debut in May. Even more striking? The pace of dealmaking. M&A involving Chinese biotech firms hit $36.9 billion in Q1more than half of global totals. Chinese biotech is having its own DeepSeek moment, said Dong Chen, chief Asia strategist at Pictet Wealth Management, referencing the AI boom that fueled Chinese tech earlier this year. Still, not everyone's chasing the highs. Some healthcare-focused funds are rotating out, preferring stable compounders with steady dividends. Others see the recent mega-deals as one-offs, and aren't ready to assign premium multiples just yet. But even with macro headwinds, analysts like those at Jefferies remain optimistic. Many Chinese biotech firms already operate as partners to U.S. drugmakers, not exportersmeaning tariffs may have limited impact. And with top scientific talent returning home amid geopolitical tensions, R&D momentum could accelerate. In short: China's biotech surge might still be in the early innings. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
